Pulmonary Arterial Hypertension Market Worth $11.0 Billion By 2030: Grand View Research, Inc.

SAN FRANCISCO, Feb. 10, 2022 /PRNewswire/ -- The global pulmonary arterial hypertension market size is anticipated to reach USD 11.0 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a lucrative CAGR of 5.2% from 2022 to 2030. The key factors driving the market growth include the increasing prevalence of pulmonary arterial hypertension, drug development and technological advancements, product approvals, and initiatives by key companies.

Key Insights & Findings from the report:

• The market was valued at USD 7.0 billion in 2021 and is expected to expand at a CAGR of 5.2% during the forecast period
• The prostacyclin and prostacyclin analogs segment held the largest share of the market by drug class in 2021. The sales of these drugs are anticipated to grow sharply in the future, primarily due to the growth expected in oral, intravenous, subcutaneous, and inhalational prostacyclin agents
• The branded drugs segment dominated the market in 2021 while the generics segment is anticipated to grow at the fastest rate from 2022 to 2030
• In 2021, the oral segment accounted for the largest revenue share of the market by route of administration owing to the greater availability of PAH formulations as oral products such as tablets, powders, and suspension
• North America dominated the market in 2021 owing to a high adoption rate and supportive infrastructure for the development and distribution of high-quality therapies. Also, the availability of reimbursement on PAH therapies supported market growth
• Asia Pacific is anticipated to witness the fastest CAGR over the forecast period due to its huge population base, rapid economic developments, and improving healthcare infrastructure

Read 150 page market research report, "Pulmonary Arterial Hypertension Market Size, Share & Trends Analysis Report By Drug Class, By Type (Branded, Generics), By Route of Administration (Oral, Intravenous/ subcutaneous, Inhalational), By Region, And Segment Forecasts, 2022 - 2030", published by Grand View Research.

The COVID-19 pandemic had a notable impact on the market. The pandemic created uncertain market conditions and lead to dampened growth. Other impacts of the pandemic include operational challenges, supply chain bottlenecks, challenges in conducting clinical trials, among others. Market players also reported a reduction in new patient starts and new patient prescriptions during 2020.

For instance, the sales of Remodulin, Tyvaso, and Orenitram were affected by the reduction in new patient starts, during the second quarter of 2020. However, the new patient starts gradually recovered to pre-pandemic numbers during the second half of 2020. Market players responded to the COVID-19 pandemic by deploying various initiatives. These included maintaining a strong financial position, maintaining ample supply of products, deploying measures to facilitate uninterrupted distribution to patients, and R&D activities among others. Overall sales of PAH drugs, however, were largely unaffected by the pandemic as market players ensured ample supply during the pandemic.

Supportive product approvals by regulatory agencies such as an extended indication of use, first generics approval, approval of drug delivery devices, etc. are estimated to fuel the market growth in the near future. In March 2021, United Therapeutics' Tyvaso received FDA clearance for use in patients with pulmonary hypertension associated with interstitial lung disease. In February 2021, the company launched- the Remunity Pump in the U.S.- a new subcutaneous delivery system for its key treprostinil product Remodulin.

Market Segmentation:

Grand View Research has segmented the pulmonary arterial hypertension market on the basis of drug class, type, route of administration, and region:

• Pulmonary Arterial Hypertension Drug Class Outlook (Revenue, USD Million, 2017 - 2030)
• Endothelin Receptor Antagonists (ERAs)
• PDE-5 Inhibitors
• Prostacyclin and Prostacyclin Analogs
• SGC Stimulators
• Pulmonary Arterial Hypertension Type Outlook (Revenue, USD Million, 2017 - 2030)
• Branded
• Generics
• Pulmonary Arterial Hypertension Route of Administration Outlook (Revenue, USD Million, 2017 - 2030)
• Oral
• Intravenous/ subcutaneous
• Inhalational
• Pulmonary Arterial Hypertension Regional Outlook (Revenue, USD Million, 2017 - 2030)
• North America
• U.S.
• Canada
• Europe
• Germany
• U.K.
• France
• Italy
• Spain
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• Latin America
• Brazil
• Mexico
• Argentina
• MEA
• South Africa
• Saudi Arabia
• UAE

List of Key Players of the Pulmonary Arterial Hypertension Market

• United Therapeutics Corporation
• Bayer
• Gilead Sciences, Inc.
• Johnson & Johnson
• Viatris Inc.
• GlaxoSmithKline
• Sandoz Inc. (Novartis)
• Lupin Pharmaceuticals, Inc.
• Sun Pharmaceutical Industries, Inc.
• Teva Pharmaceutical Industries Ltd.

Check out more studies related to pulmonary diseases diagnostics and treatment devices, published by Grand View Research:

• Pulmonary Drug Delivery Systems Market – The global pulmonary drug delivery devices/systems market is expected to grow at a CAGR of 4.7% till 2025. Increasing incidence of chronic respiratory diseases is expected to accelerate the demand for Pulmonary Drug Delivery Systems (PDDS) in the near future.
• Transcatheter Pulmonary Valve Market – The global transcatheter pulmonary valve market size is projected to grow at a CAGR of 6.0% till 2025. The market is mainly driven by the increasing prevalence of various cardiovascular diseases such as rheumatic heart disorders, hypertensive heart diseases, cerebrovascular diseases, and inflammatory heart diseases.
• Cardiopulmonary Stress Testing Devices Market – The rising prevalence of cardiovascular and pulmonary disorders such as arrhythmia and heart valve imbalance are the major factors driving the cardiopulmonary stress testing systems market. Furthermore, increasing incidences of lifestyle diseases coupled with heart and lung disorders are the factors propelling the cardiopulmonary stress testing market.

Browse through Grand View Research's coverage of the Global Pharmaceuticals Industry.

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: sales@grandviewresearch.com 
Web: https://www.grandviewresearch.com 
Grand View Compass | Grand View Pipeline 
Follow Us: LinkedIn | Twitter

Logo: https://mma.prnewswire.com/media/661327/Grand_View_Research_Logo.jpg